How is Mounjaro dosed?
The prescribing information’s own escalation schedule, the SURPASS trials it cites, its boxed warning and adverse-event table, and how research-grade tirzepatide relates to the branded product — every figure attributed to where it was read.
Topic: Reading Mounjaro’s FDA prescribing information
Audience: Anyone comparing a dosing schedule against its source
Reading time: 7–9 minutes
Not affiliated with Eli Lilly. Prof. Peptide is not affiliated with, endorsed by, or sponsored by Eli Lilly. Mounjaro is a registered trademark of Eli Lilly and Company. This page reports what Eli Lilly’s own prescribing information and FDA’s own publications state; it does not sell, ship, or recommend the branded product.
On this page
What Mounjaro is
Mounjaro is a brand name. Its active ingredient is tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Eli Lilly. The label states Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Mounjaro’s label does not cover weight reduction or obstructive sleep apnea in adults without type 2 diabetes.
Tirzepatide is also sold under a separate brand name, at different doses, for different indications — Zepbound (weight reduction and obstructive sleep apnea, without a type 2 diabetes requirement) is the same molecule with a different label. The Prof. Peptide tirzepatide profile covers how the two relate, the mechanism, and the published trial evidence across both. This page reads Mounjaro’s own label specifically, since its dosing schedule, indications, and cited trials are not identical to Zepbound’s.
What the label specifies
The table below is Mounjaro’s recommended dosage as stated in section 2.1 of its prescribing information — Eli Lilly, MOUNJARO (tirzepatide) injection prescribing information, DailyMed setid d2d7da5d-ad07-4228-955f-cf7e355c8cc0, effective August 27, 2026.
| Step | Dosage | As specified by the label |
|---|---|---|
| Starting dosage | 2.5 mg once weekly | The label states this dosage is for treatment initiation, not for glycemic control. |
| Dosage increase | +2.5 mg increments | After at least 4 weeks on the current dose, if additional glycemic control is needed. |
| Maximum dosage — adults | 15 mg once weekly | Reached only through the 2.5 mg step-wise increases above. |
| Maximum dosage — pediatric (10 years and older) | 10 mg once weekly | Reached only through the 2.5 mg step-wise increases above. |
Section 2.1 states that if a dose is missed, the label instructs administering Mounjaro as soon as possible within 4 days (96 hours) of the missed dose; if more than 4 days have passed, the label instructs skipping the missed dose and administering the next dose on the regularly scheduled day. The label also states the day of weekly administration can be changed if the time between two doses stays at least 3 days (72 hours). Section 2.2 instructs subcutaneous injection in the abdomen or thigh, or in the back of the upper arm by another person, rotating sites with each dose.
Dosage forms and strengths (section 3) list four separate presentations at the same 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per-injection strengths: single-dose pens, single-dose vials, multi-dose vials, and single-patient-use KwikPens. The multi-dose vial and KwikPen each hold 4 doses at a higher total concentration than the single-dose forms (for example, the 2.5 mg strength is 10 mg/2.4 mL, 4.17 mg/mL, in the multi-dose vial or KwikPen, versus 2.5 mg/0.5 mL in the single-dose pen or vial) — the per-injection dose is identical across all four forms; only the container and total volume differ.
The Prof. Peptide dosage calculator converts between milligram figures and syringe units for a given reconstitution; it performs the arithmetic and does not set a schedule.
What the trials administered
Section 14 of the label (Clinical Studies) names the SURPASS trials behind Mounjaro’s approved indications — SURPASS-1 through SURPASS-5, SURPASS-PEDS, and SURPASS-CVOT, each confirmed by direct search of the label text. The two below are the ones the label cites for the type 2 diabetes monotherapy and add-on dosing discussed on this page. Each is graded against Prof. Peptide’s standing citation convention — a claim is attributed when a marker resolves to a named, checkable primary source. Both grade as attributed: each is named in the label itself, with a registry number checkable against ClinicalTrials.gov independent of the label.
SURPASS-1 (NCT03954834)
40-week, double-blind, placebo-controlled monotherapy trial
Arms: Placebo (mITT N=113), MOUNJARO 5 mg (N=121), 10 mg (N=121), 15 mg (N=120) — adults with type 2 diabetes with inadequate glycemic control on diet and exercise alone
Endpoint reported: HbA1c change from baseline at week 40: −0.1% (placebo) vs. −1.8% (5 mg), −1.7% (10 mg), −1.7% (15 mg); all doses p<0.001 vs. placebo, adjusted for multiplicity.
Attributed — cited directly in the label's own Clinical Studies section (14.2), primary source open below.
SURPASS-2 (NCT03987919)
40-week, open-label (double-blind with respect to MOUNJARO dose assignment) trial, add-on to metformin
Arms: Semaglutide 1 mg (mITT N=468), MOUNJARO 5 mg (N=470), 10 mg (N=469), 15 mg (N=469) — adults with type 2 diabetes on stable metformin
Endpoint reported: HbA1c change from baseline at week 40: −1.9% (semaglutide 1 mg) vs. −2.0% (5 mg), −2.2% (10 mg), −2.3% (15 mg); 10 mg and 15 mg statistically significant vs. semaglutide.
Attributed — cited directly in the label's own Clinical Studies section (14.3), with a registry number checkable against ClinicalTrials.gov independent of the label.
Zepbound’s label cites a different trial program (Study 1 through Study 5, for weight reduction and obstructive sleep apnea) at different doses and different indications. Those figures belong to Zepbound’s own label, not Mounjaro’s, even though both products share the same active ingredient — the tirzepatide profile covers the trial evidence across both brands directly.
The label’s warnings and adverse events
Boxed warning: risk of thyroid C-cell tumors
The label states: “In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.”
The label states Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and instructs counseling patients on the potential risk and on symptoms such as a mass in the neck, dysphagia, dyspnea, or persistent hoarseness.
Table 1 of the label reports adverse reaction rates (≥5%) from a pool of placebo-controlled trials (718 patients exposed to Mounjaro, mean exposure 36.6 weeks):
| Adverse reaction | Placebo (N=235) | Mounjaro 5 mg (N=237) | Mounjaro 10 mg (N=240) | Mounjaro 15 mg (N=241) |
|---|---|---|---|---|
| Nausea | 4% | 12% | 15% | 18% |
| Diarrhea | 9% | 12% | 13% | 17% |
| Decreased appetite | 1% | 5% | 10% | 11% |
| Vomiting | 2% | 5% | 5% | 9% |
| Constipation | 1% | 6% | 6% | 7% |
| Dyspepsia | 3% | 8% | 8% | 5% |
| Abdominal pain | 4% | 6% | 5% | 5% |
Compounding and research-grade tirzepatide
Mounjaro’s prescribing information does not mention compounding. The word does not appear anywhere in the label. Everything above this section describes a prescription drug product, manufactured by Eli Lilly and dispensed by a pharmacy against a prescription.
Research-grade tirzepatide, of the kind sold by the vendors Prof. Peptide tracks elsewhere on this site, is neither the branded product described above nor a pharmacy-compounded version of it. It is sold labeled for research use, not for human administration, and it is not dispensed against a prescription.
Separately from the branded label, FDA has published its own position on compounded tirzepatide. Its April 1, 2026 statement on compounding, once the national GLP-1 supply stabilized, describes the conditions under which a compounded drug can lawfully be exempt under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, and states FDA’s position that a compounded product is treated as an unlawful copy of a commercially available drug when it shares the same active ingredient, a similar or easily substitutable strength, and the same route of administration — unless a prescriber documents a significant difference for an individual patient.
On April 30, 2026, FDA announced it is proposing to exclude tirzepatide, semaglutide, and liraglutide from the 503B bulks list entirely, stating it “did not identify a clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk drug substances.” The public comment period on that proposal closed; as of this page’s last check, FDA had not published a final determination.
None of this changes what the label above states, and none of it describes Prof. Peptide’s vendors as compounding pharmacies — they are not. It is published here because a reader comparing a branded dosing schedule against a research-grade product should be able to see, in one place, that the two are governed by different rules, and that the regulatory status of compounded tirzepatide is itself unsettled and separate from both.
How this page differs from Zepbound’s and the tirzepatide profile
Mounjaro and Zepbound share an active ingredient, and largely share the same once-weekly, 2.5 mg-increment escalation mechanics and the same 4-day missed-dose window. What differs is the label built around that molecule. Mounjaro’s label is type-2-diabetes-only — glycemic control and cardiovascular risk reduction in adults with established cardiovascular disease and type 2 diabetes — and cites the SURPASS program exclusively. Zepbound’s label covers weight reduction and obstructive sleep apnea in adults without a type 2 diabetes requirement, and cites an entirely separate set of trials (Study 1 through Study 5). A reader with type 2 diabetes and a reader without it are reading two different regulatory documents, even though the molecule injected is the same.
The tirzepatide profile is a different kind of page: it covers the molecule’s dual-agonist mechanism and the published trial evidence across both brands at once, without reading either FDA label’s escalation schedule, boxed warning, or adverse-event table in the detail this page does. This page exists because Mounjaro’s own prescribing information has figures — the missed-dose window, the SURPASS-1 and SURPASS-2 HbA1c results, the ADR percentages by dose — that the profile doesn’t report and that only Mounjaro’s own label states.
FAQ
Is Mounjaro the same as tirzepatide?
What is the starting dose on the Mounjaro label?
What is the maximum Mounjaro dose?
What happens if a dose is missed?
Does Mounjaro carry a boxed warning?
Is compounded or research-grade tirzepatide the same as Mounjaro?
References
- Eli Lilly and Company. MOUNJARO (tirzepatide) injection, for subcutaneous use — prescribing information. DailyMed, setid d2d7da5d-ad07-4228-955f-cf7e355c8cc0, effective 2026-08-27. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Drug Alerts and Statements, 2026-04-01. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. Press Announcements, 2026-04-30. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- ClinicalTrials.gov. A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Using Injectable Diabetes Medicines (SURPASS-1), NCT03954834. https://clinicaltrials.gov/study/NCT03954834
- ClinicalTrials.gov. A Study of Tirzepatide (LY3298176) Compared to Semaglutide in Participants With Type 2 Diabetes (SURPASS-2), NCT03987919. https://clinicaltrials.gov/study/NCT03987919
We may earn commissions from peptide vendor affiliate links.